In conclusion, this study supported the promising therapeutic potential of targeting TYK2 JH2 pseudokinase with small-molecule ligands that allosterically mediate the JH2-JH1 regulation to block the cytokine-induced activation of TYK2, in the development of therapeutics for multiple cytokine-driven autoimmune diseases. The gene discussed is TYK2; the disease is autoimmune disease.